Mobility Limitation: Clinical Trials

5 trials for Mobility Limitation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 completed, 1 withdrawn. 5 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 45Recruiting 2, Active not recruiting 1, Completed 1, Withdrawn 1

Follow Mobility Limitation: new trials by email Literature Review of Mobility Limitation trials Research Report on Mobility Limitation

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effectiveness and Safety of Electrically Powered Orthopedic Exercise Device for Gait Disorders
Electrically Powered Orthopedic Exercise Device - Gait Disorders
Phase 4RecruitingYonsei University302025-04-072025-08-29
TESTO-TRIAL: Use of Testosterone in Critically Ill Patients
Testosterone cypionate (200mg/3ml), Sesame oil (3ml) - Weaning Failure, Muscle Weakness
Phase 4Active not recruitingLeticia Maria Defendi Barboza Marson942024-09-092024-12-18
DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease
STIM ON plus, MED ON plus - Freezing of Gait, Parkinson Disease
Phase 4RecruitingIRCCS Istituto delle Scienze Neurologiche di Bologna202023-10-102024-03-18
Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries
Sugammadex, Neostigmine - Ambulatory Difficulty
Phase 4WithdrawnMontefiore Medical Center2019-06-202019-11-18
Impact of tDCS on Locomotion and Equilibrium in Hemiplegic Patients
anodal tDCS and sham tDCS stimulations - Gait Disorders
Phase 4CompletedAssistance Publique - Hôpitaux de Paris272014-07-102019-03-13

Narrower conditions

Critical Illness (1)  ·  Muscle Weakness (1)  ·  Parkinson Disease (1)  ·  Stroke (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (5)  ·  Signs and Symptoms (5)  ·  Nervous System Diseases (3)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Basal Ganglia Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Disease Attributes (1)  ·  Movement Disorders (1)  ·  Muscular Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Neurologic Manifestations (1)  ·  Neuromuscular Manifestations (1)

Interventions

Neostigmine (1)  ·  Sesame Oil (1)  ·  Sugammadex (1)  ·  testosterone 17 beta-cypionate (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  IRCCS Istituto delle Scienze Neurologiche di Bologna (1)  ·  Leticia Maria Defendi Barboza Marson (1)  ·  Montefiore Medical Center (1)  ·  Yonsei University (1)

Countries

Brazil (1)  ·  France (1)  ·  Italy (1)  ·  South Korea (1)

Top investigators

Curtis Choice, MD (1)  ·  Ilaria Cani (1)  ·  Na Young Kim, MD, PhD (1)

Results publications

PMID 29061169

NIH funding

2019 (1)